Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Yoland Antill; Peey-Sei Kok; Kristy Robledo; Sonia Yip; Michelle Cummins; Deborah Smith; Amanda Spurdle; Elizabeth Barnes; Yeh Chen Lee; Michael Friedlander; Sally Baron-Hay; Catherine Shannon; Jermaine Coward; Philip Beale; Geraldine Goss; Tarek Meniawy; Janine Lombard; John Andrews; Martin R Stockler; Linda Mileshkin

doi:10.1136/jitc-2020-002255

Article info

PDF

PDF +
Supplementary
Material

XML

Clinical/translational cancer immunotherapy

Original research

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Authors

Yoland Antill Medical Oncology, Cabrini Health, Malvern, Victoria, AustraliaFaculty of Medicine, Dentistry and Health Sciences, Monash University, Clayton, VIC, Australia PubMed articles Google scholar articles
Peey-Sei Kok NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Kristy Robledo NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Sonia Yip NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Michelle Cummins NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Deborah Smith Mater Pathology, Mater Research and University of Queensland, Brisbane, Queensland, Australia PubMed articles Google scholar articles
Amanda Spurdle Molecular Cancer Epidemiology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia PubMed articles Google scholar articles
Elizabeth Barnes NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Yeh Chen Lee NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, AustraliaDepartment of Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Randwick, New South Wales, AustraliaChris O'Brien Lifehouse, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Michael Friedlander Department of Medical Oncology, Prince of Wales Hospital Nelune Comprehensive Cancer Centre, Randwick, New South Wales, Australia PubMed articles Google scholar articles
Sally Baron-Hay Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia PubMed articles Google scholar articles
Catherine Shannon Mater Cancer Care Centre, Mater Hospital, South Brisbane, Queensland, Australia PubMed articles Google scholar articles
Jermaine Coward Clinical Trials Unit, Icon Cancer Care, South Brisbane, Queensland, AustraliaSchool of Medicine, University of Queensland, St Lucia, QLD, Australia PubMed articles Google scholar articles
Philip Beale Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Geraldine Goss Medical Oncology, Monash Medical Centre Clayton, Clayton, Victoria, Australia PubMed articles Google scholar articles
Tarek Meniawy Department of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia PubMed articles Google scholar articles
Janine Lombard Medical Oncology, Calvary Mater Newcastle, Hunter Region Mail Centre, New South Wales, Australia PubMed articles Google scholar articles
John Andrews NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Martin R Stockler NHMRC Clinical Trials Centre, University of Sydney, Camperdown, New South Wales, Australia PubMed articles Google scholar articles
Linda Mileshkin Department of Medical Oncology, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia PubMed articles Google scholar articles
on behalf of the Australia New Zealand Gynaecological Oncology Group (ANZGOG)
Google scholar articles

Citation

Antill Y, Kok P, Robledo K on behalf of the Australia New Zealand Gynaecological Oncology Group (ANZGOG), et al

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Journal for ImmunoTherapy of Cancer 2021;9:e002255. doi: 10.1136/jitc-2020-002255

Online issue publication

February 24, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password